Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
APGE
Upturn stock ratingUpturn stock rating

Apogee Therapeutics, Inc. Common Stock (APGE)

Upturn stock ratingUpturn stock rating
$38.12
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: APGE (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

9 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $96.75

1 Year Target Price $96.75

Analysts Price Target For last 52 week
$96.75 Target price
52w Low $26.2
Current$38.12
52w High $63.5

Analysis of Past Performance

Type Stock
Historic Profit 57.38%
Avg. Invested days 36
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.27B USD
Price to earnings Ratio -
1Y Target Price 96.75
Price to earnings Ratio -
1Y Target Price 96.75
Volume (30-day avg) 9
Beta 1.44
52 Weeks Range 26.20 - 63.50
Updated Date 08/15/2025
52 Weeks Range 26.20 - 63.50
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.14

Earnings Date

Report Date 2025-08-11
When -
Estimate -0.62
Actual -1.13

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -23.21%
Return on Equity (TTM) -34.12%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1777240111
Price to Sales(TTM) -
Enterprise Value 1777240111
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 46109800
Shares Floating 37619227
Shares Outstanding 46109800
Shares Floating 37619227
Percent Insiders 7.6
Percent Institutions 135.79

ai summary icon Upturn AI SWOT

Apogee Therapeutics, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Apogee Therapeutics is a biotechnology company focused on developing innovative biologics for the treatment of inflammatory and immunologic diseases. It was founded in 2022.

business area logo Core Business Areas

  • IgE-Mediated Diseases: Developing therapies for diseases driven by IgE antibodies, such as atopic dermatitis and asthma.
  • Other Immunologic Diseases: Exploring treatments for other immunologic conditions.

leadership logo Leadership and Structure

The company has a leadership team comprised of experienced biotechnology executives and scientists. Organizational structure follows standard biotech company lines, with research, development, clinical, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • APG777: APG777 is a lead drug candidate targeting IL-13 for atopic dermatitis. Currently in clinical trials. Market share is not yet applicable due to being in development stage. Competitors include Sanofi/Regeneron (Dupixent), Leo Pharma (Adbry).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry focused on immunology is growing, driven by increasing prevalence of autoimmune and inflammatory diseases, and advancements in biologic therapies.

Positioning

Apogee is positioning itself as a key player in developing novel biologics for immune-mediated diseases, focusing on differentiated approaches to address unmet medical needs.

Total Addressable Market (TAM)

The TAM for inflammatory and immunologic disease therapies is very large. Apogee aims to capture a share of this market through innovative approaches and clinical success. Estimate 150 Billion, Apogee aims for 5-10%.

Upturn SWOT Analysis

Strengths

  • Novel drug development platform
  • Experienced management team
  • Strong focus on immunology
  • Targeting unmet medical needs

Weaknesses

  • Early stage company
  • Reliance on clinical trial success
  • Limited financial resources compared to larger competitors

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline into new indications
  • Positive clinical trial results
  • Market approval of lead drug candidate

Threats

  • Clinical trial failures
  • Competition from established players
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • SNY
  • LLY
  • ABBV

Competitive Landscape

Apogee differentiates itself with its novel drug development platform targeting specific immunological pathways, but faces significant competition from established pharmaceutical giants with greater resources and established products.

Growth Trajectory and Initiatives

Historical Growth: Since its founding, growth is based on the progress in clinical trials and development of key therapies

Future Projections: Analyst estimates project future growth based on the successful development and commercialization of lead drug candidate, APG777.

Recent Initiatives: Advancing APG777 through clinical trials, expanding its pipeline, and securing strategic partnerships.

Summary

Apogee Therapeutics is an early-stage biotechnology company focused on novel biologics for immunology. Their lead drug candidate, APG777, shows promise, but the company faces risks associated with clinical trials and competition. Securing partnerships and successful clinical outcomes are essential for future growth. Financial resources and cashflows need to be monitored as the company grows.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and comprehensive research.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Apogee Therapeutics, Inc. Common Stock

Exchange NASDAQ
Headquaters Waltham, MA, United States
IPO Launch date 2023-07-14
CEO & Director Dr. Michael Thomas Henderson M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 196
Full time employees 196

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.